Human Genome (HGSI) has received second purchase order from the US government as an additional 45,000 doses of raxibacumab (ABthrax), for the Strategic National Stockpile, to be delivered over a three-year period. HGS expects to receive approximately $151 million from this award as deliveries are completed.
Raxibacumab is intended for the treatment of anthrax. Raxibacumab targets anthrax toxins after they are released by the bacteria into the blood and tissues.
Thomas Watkins, president and CEO of HGS, said: “We are very pleased to receive this second purchase order for raxibacumab and look forward to the continued progress of our partnership with the US Government under Project BioShield to help strengthen America’s arsenal against bioterrorism.
“We all hope never to see a large-scale version of the inhalation anthrax attacks that took place in 2001, but HGS is proud to play a role in making sure that we are prepared as a nation to limit the human cost of such an attack should it ever occur,” he added.